Aragen Bioscience offers a diverse range of oncology disease models and services to provide the most appropriate study design for your specific project. These range from human xenograft tumor models to the more complex sub-renal capsule, patient derived xenograft (PDX), and Syngeneic tumor models.
Human Cell Line Xenograft Models
There are hundreds of cell lines, various mouse strains and multiple implantation techniques that can be utilized in a xenograft model. Aragen has experience with xenograft models of lymphoma, leukemia, lung cancer, breast cancer, colon cancer, melanoma, and other indications. These can be run in nude or SCID mice as well as in the nude rat. Depending on the needs of the study and the mechanism of action of the molecules, these tumors can be implanted subcutaneously, orthotopically, within the sub-renal capsule or, in some cases, run as a metastatic model. Aragen’s team has experience with biologics and small molecule therapeutics as well as the various dosing methods and regimes required for these studies.
Syngeneic Tumor Models
If the mechanism of action requires an intact immune system, the immuno-compromised setting required for a xenograft model will not be appropriate for efficacy assessment. In such cases, syngeneic models, where the strain of the derived tumor cell line and the host animal are the same, may be more appropriate. Our team’s syngeneic model experience spans breast, colon, liver, and lung cancers as well as melanoma and lymphoma models.
Patient Derived Xenograft Tumor Models
Patient derived xenografts (PDX) are used to create an environment that promotes the natural growth of cancer and can aid treatment evaluations for the original patient. By implanting tumor tissue derived directly from human patients into immuno-compromised mice, Aragen has evaluated a number of compounds in PDX models and has gained significant experience with this novel model class.